Anaya-Delgadillo G, Velasco-Torre A

Language: Spanish
References: 31
Page: 79-82
PDF size: 622.33 Kb.

ABSTRACT

Ependymomas are tumors of the central nervous system with an anual report of 0.24 every 100 00 inhabitants. About 16% of the medular ependymomas are presented in the lumbo sacral region and the most common histopathological variant is the myxopapillar according to the latest classification system by the World Health Organization (WHO). The clinical presentation of the ependymomas of the filium terminale can be long term radicular syndrome. The diagnosis can be established by MRI, but the definitive will be determined with a biopsy. The main treatment is surgery to remove the tumor; chemotherapy and radiotherapy may be necessary in some cases. Some immunohystochemistry markers like p53 y Ki67 have been related to the prognosis. We present the clinical case of a patient who presented radicular syndrome and the diagnosis of myxopapillary ependymoma was made, adjuvant treatment with chemo and radiotherapy was also required. We also performed research of the latest literature.

REFERENCES

1. 1.Terapor PE, et al. Pathology of spinal ependymomas: an institutional experience over 25 years in 134 patients. Neurosurgery 2013; 73: 247-255.

2. 2.Gelabert–González M, et al. Ependimomas del filum terminal. Análisis de 20 casos consecutivos. Neurocirugia (Astur). 2010;21(5):381-9

3. 3.Santiesteban-Velázquez NJ, et al. Ependimoma mixopapilar: reporte de un caso a forma de recaídas y remisiones. Rev Cubana Neurol of Neurocir. 2012; 2(1): 40-42.

4. 4.Medina-Sansón A, et al. Protocolo de Tratamiento de Ependimomas del Hospital Infanitl de México “Federico Gómez” departamento de Oncología. G u í a s M e d i c a s 2 0 1 1 . http://www.himfg.edu.mx/descargas/documentos/ planeacion/guiasclinicasHIM/Ependimomas.pdf (2011 accessed march 2014).

5. 5.Diagnóstico y Tratamiento del Ependimoma en Niños. México. Secretaria de Salud, 2010.

6. 6.Stephen JH, et al. Spinal cord ependymomas and myxopapillary ependymomas in ther firs 2 decades of life: a clinicopathological and ummunohistochemical charactrization of 19 cases. J Neurosurg Pediatr. 2012;9(6):646-53.

7. 7.Kocka Z, et al. Spinal cord ependymomas in adults: analysis of 15 cases. J Exp Clin Cancer Res. 2004; 23(2): 201-206.

8. 8.- National Cancer Institute at the National Institutes of Health. Clasificación histopatologico de los tumores ependimarios infantiles. http://www.cancer.gov/espanol/pdq/tratamiento/e pendimomainfantil/HealthProfessional/page2 (Febrero 2014 accessed March 2014).

9. 9.Combs SE, et al. Local radiotherapeutic management of ependymomas with fractionated stereotactic radiotherapy (FSRT). BMC Cancer. 2006; 16: 222-230.

10. 10.Godfraind, C. Classification and controversies in pathology of ependymomas. Childs Nerv Syst. 2009;25(10):1185-93.

11. Fassett DR, Schmidt MH. Lumbos acral ependymomas: a review of the management of intradural and extradural tumors. Neurosurg Focus. 2003; 15(5): 13.

12. 12.Hanbali F, et al. Spinal cord ependymoma: radical surgical resection and outcome. Neurosurgery. 2002; 51(5):1162-72.

13. 13.Fabra-Noguera A, et al. Ependimoma mixopapilar. Butlletín 2010: 28: 3.

14. 14.Martìnez-Suarez JE, et al. Ependimoma mixopapilar dorsolumbar. Reporte de un caso. Rev. Chil. Neurocirugía 2011 (36); 6: 69-71

15. 15.López-Aguilar E, et al. Factores pronósticos de pacientes pediátricos con ependimomas. Gac Méd Méx 2009; 145(1): 7-13.

16. 16.Kotani T, et al. Mobile ependymoma diagnosed with cine MRI. BMJ Case Rep 2014;19; 13.

17. 17.Millesi M, et al. Analysis of 5-amonilevulinic acidinduces fluoresence in 55 different spinal tumors. Neurosurg Focus 2014; (36) 1-11.

18. 18.- Kochbati L, et al. Primary intramedullary ependymomas: retrospective study of 16 cases. Cancer Radiother. 2003; 7(1): 17-21.

19. 19.González-Navarro DA, et al. Análisis descriptivo y de la supervivencia del ependimoma en la comunidad de Madrid. In: XV jornadas de medicina preventiva y salud pública de la Universidad Complutense de Madrid. España. 2009.

20. Lin YH, et al. Treatment of spinal cordepen dymomas by surgery wi thor witho ut postoperative radiotherapy. J Neuro-Oncol (2005) 71: 205–210.

21. 21.Rushing EJ, Brown DF, Hladik CL, et al. Correlation ofbcl-2, p 53 and MIB - 1 expression w i t h ependymoma grade and subtype. Mod Pathol. 1998 May;11(5):464-70.

22. 22.Prayson RA. Myxopapillary ependymomas: a clinicopathologic study of 14 cases including MIB-1 and p53 immunoreactivity. Mod Pathol. 1997; 10(4):304-10.

23. 23.Sgouros S, et al. Spinal ependymomas the cvalue of postoperative radiotherapy for residual disease control. Br J Neurosurg. 1996;10(6):559-66.

24. 24.- Del Valle-Robles R, et al. Requerimientos para la operación y control de calidad en los servicios de radiocirugía y radioterapia estereotactica. Rev. Medica Sur. 2002; 9:119-126.

25. 25 . - Reni M, Gatta G, Mazza E, Vecht C. Ependymoma. Crit Rev Oncol Hematol. 2007; 63: 81- 89.

26. 26.Gil-Salú JL, Domínguez-Pascual I, Pérez-Requena J, et al. Características citomorfológica s e inmunohistoquímicas de cultivos primarios obtenidos a partir de tumores cerebrales. Rev Esp de Patol. 2002; (35) 207-212.

27. 27.Yan X, Cheng X Liu J,et al. Clinicopathological evaluation of inmunohistochemical Ki-67 and endothelial nitric oxide synthase expression in intracranial ependymoma. Clun Invest Med. 2008; 31(4): 206-211.

28. 28.Suri Suri VS1, Tatke M, Singh D et al. Histological Spectrum of Ependymomas and Correlation of p53 and Ki67 Expression with Ependymoma Grade and Subtype. Indian J Cancer. 2004 Apr-Jun;41(2):66-71.

29. 29.Kuncova K, Janda A, Kasal P, Zamecnik J. Immunohistochemical prognostic markers in intracranial ependymomas: systematic review and meta-analysis. Pathol Oncol Res. 2009 Dec;15(4):605- 14.

30. 30.Pencovich N, Bot G, Lidar Z, et al. Spinal ependymoma with regionalmet astasisat presentation. Acta Neurochir (Wien). 2014 Jun; 156(6):1215-22.

31. 31.Antony R, Wong Ke, Patel M, et al. A restrospective analysis of recurrent intracranial ependymoma. Pediatr Blood Cancer 2014; 61:1195–1201.